Last updated on March 2020

A Study of WVT078 in Patients With Multiple Myeloma (MM)

Brief description of study

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 in patients relapses and/or refractory Multiple Myeloma (MM)

Detailed Study Description

This first-in-human trial with WVT078 is a dose escalation study whose primary purpose is to characterize the safety, tolerability, and determine recommended dose regimen(s) of WVT078 in subjects with MM who have received two or more standard of care lines of therapy including an IMID, a proteasome inhibitor, and an anti-CD38 agent (if available) and are relapsed and/or refractory to or intolerant of each regimen. In addition, this study will assess preliminary anti-MM response of and characterize the pharmacokinetics and immunogenicity of WVT078. The results of this study will inform the future development of WVT078 as a treatment for relapsed and/or refractory MM.

Clinical Study Identifier: NCT04123418

Find a site near you

Start Over

Novartis Investigative Site

Prahran, Australia
  Connect »